HER2 mutations in NSCLC predominantly manifest in specific patient subsets, primarily women, never-smokers, and those diagnosed with adenocarcinoma women, never-smokers, and adenocarcinoma patients (Pillai et al. 2017). This evidence concerns the gene ERBB2 and adenocarcinoma.